Inspire Medical Systems, Inc. (NYSE:INSP) Stake Reduced by Apollon Wealth Management LLC

Apollon Wealth Management LLC cut its holdings in Inspire Medical Systems, Inc. (NYSE:INSP) by 5.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,180 shares of the company’s stock after selling 229 shares during the quarter. Apollon Wealth Management LLC’s holdings in Inspire Medical Systems were worth $775,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. True Wealth Design LLC bought a new stake in Inspire Medical Systems in the third quarter worth about $30,000. Farther Finance Advisors LLC raised its holdings in Inspire Medical Systems by 1,158.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 151 shares of the company’s stock worth $32,000 after buying an additional 139 shares during the period. GAMMA Investing LLC raised its holdings in Inspire Medical Systems by 559.3% during the 3rd quarter. GAMMA Investing LLC now owns 178 shares of the company’s stock worth $38,000 after buying an additional 151 shares during the period. Signaturefd LLC raised its holdings in Inspire Medical Systems by 45.9% during the 3rd quarter. Signaturefd LLC now owns 270 shares of the company’s stock worth $57,000 after buying an additional 85 shares during the period. Finally, Nisa Investment Advisors LLC raised its holdings in Inspire Medical Systems by 37.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 368 shares of the company’s stock worth $68,000 after buying an additional 100 shares during the period. 94.91% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on INSP shares. Wells Fargo & Company cut their price objective on Inspire Medical Systems from $198.00 to $195.00 and set an “equal weight” rating on the stock in a report on Tuesday. Royal Bank of Canada restated an “outperform” rating and set a $260.00 price objective on shares of Inspire Medical Systems in a report on Tuesday. Bank of America upgraded Inspire Medical Systems from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $220.00 to $255.00 in a report on Wednesday, November 20th. Robert W. Baird cut their price objective on Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating on the stock in a report on Tuesday. Finally, Piper Sandler dropped their target price on Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating on the stock in a report on Monday. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $228.82.

Inspire Medical Systems Stock Performance

Shares of NYSE INSP opened at $183.17 on Wednesday. The stock has a market cap of $5.49 billion, a price-to-earnings ratio of 171.18 and a beta of 1.32. The business has a 50 day simple moving average of $189.57 and a 200 day simple moving average of $190.98. Inspire Medical Systems, Inc. has a 52 week low of $123.00 and a 52 week high of $257.40.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings results on Monday, February 10th. The company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 5.30% and a net margin of 4.37%. On average, analysts predict that Inspire Medical Systems, Inc. will post 1.33 EPS for the current year.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.